水飞蓟在治疗慢性肝炎中的研究进展

doi:10.12092/j.issn.1009-2501.2019.05.015

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (5): 573-579.doi: 10.12092/j.issn.1009-2501.2019.05.015

水飞蓟在治疗慢性肝炎中的研究进展

翟硕^1,2，李娜³，陈蓓宁⁴，寇俊萍⁵，邢为藩⁴，张评浒²

¹中国药科大学江苏省新药筛选重点实验室，南京 210009，江苏；²扬州大学医学院（转化医学研究院）& 江苏省中西医结合老年病防治重点实验室，扬州 225001，江苏； ³中国药科大学，中国药科大学学报编辑部，南京 210009，江苏； ⁴南京宸翔医药有限公司，南京 211006，江苏； ⁵江苏省中药评价与转化重点实验室，南京 211198，江苏

收稿日期:2018-11-28 修回日期:2018-12-23 出版日期:2019-05-26 发布日期:2019-05-28
通讯作者: 张评浒，男，博士，特聘教授，研究方向为抗病毒药物药理学。 E-mail：zhangpinghu@163.com 寇俊萍,女，教授，研究方向：中药药理学。
作者简介:翟硕，女，硕士研究生，研究方向为药理学。 Tel：18752545876 E-mail：shuozhai1@126.com
基金资助:
十三五重大新药创制（2017ZX09301050）；江苏省人兽共患病学重点实验室开放课题（R1707）；青海省高端创新人才项目

Prospective of a natural remedy, silymarin from milk thistle, for treating chronic hepatitis

ZHAI Shuo ^1,2，LI Na ³，CHEN Beining⁴，KOU Junping ⁵，XING Weifan ⁴，ZHANG Pinghu ²

¹Jiangsu Key Lab for New Drug Screening，China Pharmaceutical University，Nanjing 210009, Jiangsu, China; ² Medical College(Institute of Translational Medicine) & Jiangsu Key laboratory of integrated traditional Chinese and Western Medicine for prevention and treatment of Senile Diseases,Yangzhou University,Yangzhou 225001,Jiangsu,China；³ Periodical Department of China Pharmaceutical University，Nanjing 210009,Jiangsu,China；⁴Nanjing Chenxiangyiyao Co.,Ltd，Nanjing 211006,Jiangsu,China；⁵ Jiangsu Key Laboratory of Evaluation and Transformation of Traditional Chinese Medicine，China Pharmaceutical University,Nanjing 211198，Jiangsu,China

Received:2018-11-28 Revised:2018-12-23 Online:2019-05-26 Published:2019-05-28

摘要/Abstract

摘要：

水飞蓟（Silybum marianum）是菊科水飞蓟属植物，其种子含有的黄酮类天然产物水飞蓟素具有抗氧化、抗炎、抗癌、保肝降酶、降脂等多种药理活性，且临床对病毒性肝炎、药物性肝炎、酒精性肝炎、自身免疫性肝炎等肝脏疾病均有显著疗效。本文就经典保肝药-水飞蓟素在治疗各类肝脏疾病中的研究进展及机制进行了综述，以期为水飞蓟素在抗肝炎领域的再次开发应用提供参考。

关键词: 水飞蓟, 慢性肝炎, 保肝降酶, 细胞因子, 免疫

Abstract:

Silybum marianum is a plant of the genus salicaceae,and its flavonoid natural product silymarin has many pharmacological activities such as anti-oxidation,anti-inflammatory,anti-cancer,liver-protecting,lipid-lowering,etc.It has significant effects on liver diseases such as viral hepatitis,drug-induced hepatitis,alcoholic hepatitis,and autoimmune hepatitis.This article reviews the research progress and mechanism of classic hepatoprotectant-silymarin in the treatment of various liver diseases,in order to provide reference for the re-development and application of silymarin in the field of anti-hepatitis.

Key words: milk thistle, silybin, chronic hepatitis, liver protection, cytokines

中图分类号:

R285
R51

翟硕，李娜，陈蓓宁，寇俊萍，邢为藩，张评浒. 水飞蓟在治疗慢性肝炎中的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(5): 573-579.

ZHAI Shuo，LI Na，CHEN Beining，KOU Junping，XING Weifan，ZHANG Pinghu. Prospective of a natural remedy, silymarin from milk thistle, for treating chronic hepatitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 573-579.

参考文献

［1］张通,郭万里,聂作明,等.水飞蓟的基源鉴定与质量分析［J］.浙江理工大学学报(自然科学版),2017,37(3):467-474.
［2］Wang H, Yan T, Xie Y,et al. Mechanism-based inhibitory and peroxisome proliferator-activated receptor alpha-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes ［J］. Drug Metab Dispos, 2015，43(4): 444-454.
［3］Neha, Jaggi AS, Singh N. Silymarin and its role in chronic diseases［J］.Adv Exp Med Biol, 2016,929:25-44.
［4］Federico A, Dallio M, Loguercio C. Silymarin/Silybin and chronic liver disease: a marriage of many years［J］. Molecules, 2017, 22 (2): pii: E191.
［5］Li HB, Yang YR, Mo ZJ, et al. Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition［J］.Braz J Med Biol Res, 2015,48(5):440-446.
［6］Sornsuvit C, Hongwiset D, Yotsawimonwat S, et al. The bioavailability and pharmacokinetics of silymarin SMEDDS formulation study in healthy thai volunteers［J］. Evid Based Complement Alternat Med, 2018, 2018:1507834.
［7］Zarrelli A, Romanucci V, Tuccillo C, et al. New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties ［J］. Bioorg Med Chem Lett, 2014, 24(22):5147-5149.
［8］向英歌. 张武主任治疗慢性肝炎学术经验总结及临床研究［D］.中国中医科学院,2016.
［9］邢杰,陈英利,陶淑华,等.免疫性肝损伤相关细胞因子研究进展［J］.中国病原生物学杂志,2009,4(1):71-72,75.
［10］Cruz HM, Barbosa JR, Baima Colares JK, et al. Cross-sectional study to determine viral hepatitis knowledge in different urban populations in Brazil［J］. World J Hepatol, 2018, 10(11):867-876.
［11］Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection ［J］. World J Gastroenterol, 2012, 18(20): 2443-2451.
［12］Kayaaslan B, Akinci E, Ari A, et al. A long-term multicenter study: entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients［J］. Clin Res Hepatol Gastroenterol, 2018,42(1):40-47.
［13］Umetsu T, Inoue J, Kogure T, et al. Inhibitory effect of silibinin on hepatitis B virus entry［J］. Biochem Biophys Rep, 2018,14:20-25.
［14］曾传莉,胡爱荣,胡耀仁,等.恩替卡韦联合微生态制剂治疗乙肝肝硬化患者的临床疗效研究［J］.中国临床药理学与治疗学,2018,23(7):796-801.
［15］卓燊,陈君,秦海洸.水飞蓟宾磷脂复合物联合阿德福韦酯对56例慢性乙肝患者疗效观察［J］. 中国药物经济学, 2014,9(1): 229-230.
［16］张友琴.拉米夫定联合水飞蓟宾葡甲胺片治疗慢性乙型肝炎的疗效观察［J］.临床医药文献电子杂志,2016,3(7):1335,1338.
［17］Lovelace ES, Wagoner J, MacDonald J, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling ［J］. J Nat Prod, 2015,78(8):1990-2000.
［18］Vecchione G, Grasselli E, Voci A, et al. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells ［J］. World J Gastroenterol, 2016, 22(26): 6016-6026.
［19］Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy ［J］. Gastroenterology, 2008, 135(5): 1561-1567.
［20］DebRoy S, Hiraga N, Imamura M, et al. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy［J］. J Viral Hepat, 2016, 23(9):708-717.
［21］Blaising J, Lévy PL, Gondeau C, et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking［J］. Cell Microbiol, 2013, 15(11):1866-1882.
［22］Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase ［J］. Gastroenterol, 2010, 138(3): 1112-1122.
［23］袁玲,杨永耿,沈有秀,等.药物性肝损伤的研究进展［J］.临床肝胆病杂志,2017,33(2):375-378.
［24］姬粉芝,刘俊巧.水飞蓟宾胶囊治疗抗结核药物性肝炎的疗效探讨［J］.中国继续医学教育,2016,8(34):184-186.
［25］张红.水飞蓟宾治疗抗精神病药物引起的肝功能损害的疗效观察［J］.新疆医学,2014,44(10):27-28.
［26］Papackova Z, Heczkova M, Dankova H, et al. Silymarin prevents acetaminophen-inducedhepatotoxicity in mice［J］. PLoS ONE,2018,13(1):e0191353.
［27］Ramakrishnan G, Lo Muzio L, Elinos-Baez CM, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells［J］. Cell Prolif,2009,42(2):229-240.
［28］Xiang X, You XM, Zhong JH, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection ［J］. J Hepatol, 2017, 67(4):885-886.
［29］Kim JS, Han NK, Kim SH, et al. Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal transition［J］. Oncotarget, 2017, 8(41):69386-69397.
［30］Stickel F, Datz C, Hampe J, et al. Pathophysiology and management of alcoholic liver disease: update 2016［J］. Gut Liver, 2017, 11(2):173-188.
［31］Zeng T, Zhang CL, Xiao M, et al. Critical roles of kupffer cells in the pathogenesis of alcoholic liver disease: from basic science to clinical trials［J］. Front Immunol, 2016, 7:538.
［32］姚祥,蒋静.酒精肝的临床症状及水飞蓟宾对酒精肝的治疗分析［J］.当代医学,2017,23(13):62-63.
［33］Federico A, Dallio M, DI Fabio G, et al. Silybin-phosphatidylcholine complex protects human gastric and liver cells from oxidative stress［J］. In Vivo, 2015, 29(5):569-575.
［34］Das SK, Mukherjee S. Biochemical and immunological basis of silymarin effect, a milk thistle (Silybum marianum) against ethanol-induced oxidative damage［J］.Toxicol Mech Methods, 2012,22(5):409-413.
［35］Kapila N, Higa JT, Longhi MS, et al. Autoimmune hepatitis:clinical review with insights into the purinergic mechanism of disease［J］. J Clin Transl Hepatol, 2013, 1(2):79-86.
［36］Ma WT, Chang C, Gershwin ME, et al. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review ［J］. Autoimmun, 2017, 83: 95-112.
［37］黄巧玲.自身免疫性肝炎的诊断及治疗研究进展［J］.内科,2017,12(1):43-45,62.
［38］张永州,吴先闯,刘瑜新,等.水飞蓟素对伴刀豆球蛋白A致免疫性肝损伤小鼠的保护作用［J］.中国新药与临床杂志,2017,36(7):417-420.
［39］黄彩玲,肖柳英,潘竞锵.水飞蓟素对小鼠肝损伤保护作用及机理研究［J］.中国民族民间医药,2012,21(15):36-38.
［40］Abenavoli L,Milic N.Silymarin for liver disease［J］. Liv Pathophysiol,2017,621-631.DOI:10.1016/B978-0-12-804274-8.00045-X.
［41］王川雨,林尤直.阿德福韦酯联合水飞蓟宾治疗慢性乙型肝炎合并脂肪肝疗效探讨［J］.中国实用医药,2018,13(23):95-97.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.
[4]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[5]	蔡祖欢, 邓桃妹, 魏奶杰, 朱丹, 钱斐, 王广基, 张经纬. 水飞蓟宾改善非酒精性脂肪性肝炎小鼠脂质代谢紊乱[J]. 中国临床药理学与治疗学, 2023, 28(3): 241-248.
[6]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[7]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[8]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[9]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[10]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[11]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[12]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[13]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[14]	彭静, 宋静, 栾家杰. 新型冠状病毒肺炎治疗新策略：间充质干细胞疗法[J]. 中国临床药理学与治疗学, 2021, 26(9): 1073-1079.
[15]	车津晶, 李娜. 生物类似药临床免疫原性相似性评价生物分析方法的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(7): 721-728.

水飞蓟在治疗慢性肝炎中的研究进展

Prospective of a natural remedy, silymarin from milk thistle, for treating chronic hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价